ChemBioDefense November, 2003

In vitro Characterization of Recombinant Human BuChE (Protexia) as a Potential Bioscavenger

David E. Lenz, Ph.D.,
Pharmacology Division
U.S. Army Medical Research Institute of Chemical Defense
Aberdeen Proving Ground, MD 21010

USAMRICD

Report Documentation Page

Form Approved
OMB No. 0704-0188

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
01 OCT 2005	**N/A**	**-**

4. TITLE AND SUBTITLE	5a. CONTRACT NUMBER
In vitro Characterization of Recombinant Human BuChE (Protexia) as a Potential Bioscavenger	5b. GRANT NUMBER
	5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S)	5d. PROJECT NUMBER
	5e. TASK NUMBER
	5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) **Pharmacology Division U.S. Army Medical Research Institute of Chemical Defense Aberdeen Proving Ground, MD 21010**	8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)	10. SPONSOR/MONITOR'S ACRONYM(S)
	11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION/AVAILABILITY STATEMENT
Approved for public release, distribution unlimited

13. SUPPLEMENTARY NOTES
See also ADM001851, Proceedings of the 2003 Joint Service Scientific Conference on Chemical & Biological Defense Research, 17-20 November 2003. , The original document contains color images.

14. ABSTRACT

15. SUBJECT TERMS

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			
unclassified	**unclassified**	**unclassified**	**UU**	**20**	

Co-Authors

D.M. Cerasoli[1], E.M. Griffiths[1], B. P. Doctor[2], A. Saxena[2], N.H. Greig[3], Q.S. Yu[3], .Y. Huang[4], H. Wilgus[4] and C. N. Karatzas.[4]

[1]Pharmacology Division, USAMRICD, 3100 Ricketts Pt. Rd, APG, MD 21010

[2] Biochemistry Division, 503 Robert Grant Dr., WRAIR, Bethesda, MD 20910

[3] Drug Design & Development Section, NIA, 5600 Nathan Shock Drive, Baltimore, MD 21224

[4] Nexia Biotechnologies Inc, 1000 St. Charles Ave, Block B, Vaudreuil-Dorion, Quebec, J7V8P5 Canada

USAMRICD

Objectives

- **Demonstrate improved medical protection against nerve agents**
- **Develop a prophylactic that detoxifies nerve agents at a rate sufficient to protect against $5LD_{50}$ exposure**
- **Prophylactic should:**
  - Be non-toxic
  - Produce no adverse side effects
  - Have no adverse effect on performance
  - Be easy to administer
  - Have a long biological half-life



3-D model of BuChE allows for rational drug design and molecular biology approaches to development of biological scavengers.

USAMRICD

Concept

- Provide a pretreatment capable of protecting against up to 5xLD_{50} of nerve agent with no side effects and no need for additional protective clothing or therapy

Potential Bioscavengers

Efforts to date have focused on BuChE of human origin

- Production of Hu BChE From Cohn Fraction IV-4
  - single band on SDS-PAGE
  - ~ 20 g =14 million units of purified BChE
  - >98% pure; specific activity ~700 U/mg

- Material (Protexia™) from milk of transgenic goats is now available
  - Hu-BuChE gene fused to a milk promoter
  - Expression is directed to the milk of transgenic goats
  - Purified material has Specific activity ~595 U/mg

Need to characterize Protexia™ versus plasma derived material

Protexia™ Binds H³-Soman



USAMRICD

Protexia™ Binds H^3-DFP



Protexia™ BuChE is Inhibited by OPs



USAMRICD

Titration of h-BuChE and Protexia™ by Soman and VX





USAMRICD

Structures of Inhibitors

Pyridostigmine bromide



Structures of Inhibitors



Phenserine



Tolserine



Phenethylcymserine tartrate



Ethylcarbamoyl

USAMRICD

Tolserine with h-BuChE



USAMRICD

Tolserine with h-BuChE



USAMRICD

Tolserine with RHu-BuChE (Protexia™)



USAMRICD

Tolserine with Protexia™



USAMRICD

Phenserine with h-BuChE



USAMRICD

Phenserine with Protexia™



USAMRICD

K_i and IC50 data for Set of Inhibitors

Inhibitor compound	Protexia™ IC 50	Protexia™ K_i (M)	Hu-BuChE IC 50	Hu-BuChE K_i (M)
Phenserine	5×10^{-7}	1.3×10^{-6}	5×10^{-7}	6.6×10^{-7}
Tolserine	8×10^{-8}	1.4×10^{-7}	5×10^{-8}	7.3×10^{-8}
Phenethyl cynserine	5×10^{-11}	5.1×10^{-10}	1×10^{-10}	1.8×10^{-8}
Ethyl carbamoyl	5×10^{-11}	6.2×10^{-10}	5×10^{-14}	1.9×10^{-13}
Pyridostigmine bromide	5×10^{-7}	4.6×10^{-7}	3×10^{-7}	6.2×10^{-7}

Comparison of Hu-BuChE and ProtexiaTM

- In vitro comparison of both forms of human BuChE with a variety of inhibitors

- Properties of recombinant HuBuChE from milk of transgenic goats (Protexia™)

  - **Binds the nerve agents GA, GB, GD, VX**
  - **In vitro properties similar to human plasma BuChE**

- Results to date support similarity in the two sources.

Summary

Plasma BuChE is current standard.

- **Provides protection**
- **PK known in three species**

Protexia™ binds all nerve agents

- **Binding is active site specific**
- **Reaction with a variety of inhibitors is the same for both types of BuChE**

While further characterization of Protexia™ is needed to include PK and efficacy data, in vitro tests suggest both forms of the enzyme behave in a similar manner.